Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGF-β1 and VEGF expression in rat peritoneal mesothelial cells

American Journal of Nephrology

Volumn 30, Issue 3, 2009, Pages 295-302

  Mizuiri, Sonoo ^a   Ohashi, Yasushi ^a   Hemmi, Hiromichi ^b   Arita, Michitsune ^b   Yamada, Kanae ^b   Aoki, Toshiyuki ^a   Miyagi, Moriatsu ^a   Sakai, Ken ^a   Aikawa, Atsushi ^a  

^a TOHO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AT1 receptor blocker; Peritoneal dialysis solution; Peritoneal mesothelial cells; Pyridoxamine; Transforming growth factor 1; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIANEAL; EXTRANEAL; GLUCOSE; MESSENGER RNA; N 10; OLMESARTAN; PHOSPHATE BUFFERED SALINE; PYRIDOXAMINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL STUDY; GLYCATION; GROWTH; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; MESOTHELIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERITONEAL DIALYSIS; PERITONEUM CELL; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CELLS, CULTURED; EPITHELIAL CELLS; HEMODIALYSIS SOLUTIONS; MALE; PERITONEAL DIALYSIS; PERITONEUM; PYRIDOXAMINE; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67449113449     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000225929     Document Type: Article

References (37)

1. Honda K, Nitta K, Horita S, et al: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-176.
2. Williams JD, Craig KJ, Topley N, et al: Morphological changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
3. Wong TY, Phillips AO, Witowski J, et al: Glucose-mediated induction of TGF-beta 1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int 2003; 63: 1404-1416.
4. Yao Q, Pawlaczyk K, Ayala ER, et al: The role of the TGF/Smad pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. Nephron Exp Nephrol 2008; 109:e71-e78.
5. De Vriese AS, Tilton RG, Mortier S, et al: Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21: 2549-2555.
6. Margetts PJ, Bonniaud P: Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-541.
7. Aroeira LS, Aguilera A, Sánchez-Tomero JA, et al: Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007; 18: 2004-2013.
8. Krediet RT, Zweers MM, van der Wal AC, et al: Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000; 20(suppl 2):S19-S25.
9. Inagi R, Miyata T, Yamamoto T, et al: Glucose degradation product methyglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alternations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463: 260-264.
10. Mandel-Weber S, Cohen CD, Haslinger B, et al: Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002; 61: 570-578.
11. Ha H, Cha MK, Choi HN, et al: Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22: 171-177.
12. Aroeira LS, Aguilera A, Selgas R, et al: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J kidney Dis 2005; 46: 938-948.
13. Kyuden Y, Ito T, Masaki T, et al: TGF- 1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005; 25: 483-491.
14. Noh H, Ha H, Yu MR, et al: Angiotensin II mediates high glucose-induced TGF- 1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005;25: 38-47.
15. Miyata T, van Ypersele de Strihou C, Ueda Y, et al: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487.
16. Booth AA, Khalifah RG, Hudson BG: Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996; 220: 113-119.
17. Hjelle JT, Golinska BT, Waters DC, et al: Isolation and propagation in vitro of peritoneal mesothelial cells. Perit Dial Int 1989; 9: 341-347.
18. Pötzsch B, Grulich-Henn J, Rössing R, et al: Identification of endothelial and mesothelial cells in human omental tissue and in omentum-derived cultured cells by specific cell markers. Lab Invest 1990; 63: 841-852.
19. Ha H, Yu MR, Choi HN, et al: Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 2000; 20:S10-S18.
20. Nilsson-Thorell CB, Muscalu N, Andrén AH, et al: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993; 13: 208-213.
21. Stylianou E, Jenner LA, Davies M, et al: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990; 37: 1563-1570.
22. Gallagher S, Winston SE, Fuller SA, et al: Immunoblotting and immunodetection. Curr Protoc Immunol 2008;Nov;Chapter 8:Unit 8.10.
23. Ota T, Takamura T, Ando H, et al: Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843-851.
24. Ames MH: More on the means comparison with unequal variances problem. J Biopharm Stat 1996; 6: 177-183.
25. Bender TO, Witowski J, Korybalska K, et al: Reduced viability of human peritoneal mesothelial cells (HPMC) following 'chronic' exposure to differently sterilized peritoneal dialysis fluids (PDF) (Abstract). Perit Dial Int 2000; 20(suppl 1):S9.
26. Mortier S, Faict D, Schalkwijk CG, et al: Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-1265. (Pubitemid 39121036)
27. ter Wee PM, van Ittersum FJ: The new peritoneal dialysis solutions: friends only, or foes in part? Nat Clin Pract Nephrol 2007; 3: 604-612.
28. Williams JD, Topley N, Craig KJ, et al: The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-418.
29. Fusshoeller A, Baehr J, Grabensee B, et al: Biocompatibility of a bicarbonate/lactatebuffered PD fluid tested with a doublechamber cell culture system. Perit Dial Int 2005; 25: 387-393.
30. Jones S, Holmes CJ, Krediet RT, et al: Bicarbonate/ lactate-based solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-1538.
31. Lamb E, Cattell WR, Dawnay A: Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Sci 1993; 84: 619-626.
32. Martikainen TA, Teppo AM, Grönhagen-Riska C, et al: Glucose free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25: 453-460.
33. Moriishi M, Kawanishi H, Watanabe H, et al: Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane. Adv Perit Dial 2005; 21: 21-24.
34. Kakuta T, Tanaka R, Satoh Y, et al: Pyridoxamine improves functional, structural, and biochemical alterations and peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int 2005; 68: 1326-1336.
35. Sauter M, Cohen CD, Wörnle M, et al: ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int 2007; 27: 167-172.
36. Degenhardt TP, Alderson NL, Arrington DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950.
37. Yung S, Li FK, Chan TM: Technological advances in peritoneal dialysis research. Peritoneal mesothelial cell culture and biology. Perit Dial Int 2006; 26: 162-173.